Clinical trial NCT00194896 - References

Type 2 Diabetes Mellitus — Preferred Treatment of Type 1.5 Diabetes

Citation(s)

•   Antonucci T, Whitcomb R, McLain R, Lockwood D, Norris RM
  Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care. 1997 Feb;20(2):188-93. Erratum in: Diabetes Care 1998 Apr;21(4):678.
•   Atkinson MA, Maclaren NK, Luchetta R
  Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes. 1990 Aug;39(8):933-7.
•   Brooks-Worrell BM, Juneja R, Minokadeh A, Greenbaum CJ, Palmer JP
  Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes. 1999 May;48(5):983-8.
•   DeFronzo RA
  Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia. 1992 Apr;35(4):389-97. Review.
•   Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C
  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86.
•   Diabetes Prevention Trial--Type 1 Diabetes Study Group
  Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002 May 30;346(22):1685-91.
•   Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial
  A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med. 1998 Apr 1;128(7):517-23.
•   Gleichmann H, Zörcher B, Greulich B, Gries FA, Henrichs HR, Betrams J, Kolb H
  Correlation of islet cell antibodies and HLA-DR phenotypes with diabetes mellitus in adults. Diabetologia. 1984 Jul;27 Suppl:90-2.
•   Gotfredsen CF, Buschard K, Frandsen EK
  Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia. 1985 Dec;28(12):933-5.
•   Groop L, Miettinen A, Groop PH, Meri S, Koskimies S, Bottazzo GF
  Organ-specific autoimmunity and HLA-DR antigens as markers for beta-cell destruction in patients with type II diabetes. Diabetes. 1988 Jan;37(1):99-103.
•   Groop LC, Bottazzo GF, Doniach D
  Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis. Diabetes. 1986 Feb;35(2):237-41.
•   Hagopian WA, Karlsen AE, Gottsäter A, Landin-Olsson M, Grubin CE, Sundkvist G, Petersen JS, Boel E, Dyrberg T, Lernmark A
  Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type. J Clin Invest. 1993 Jan;91(1):368-74.
•   Hao W, Li L, Mehta V, Lernmark A, Palmer JP
  Functional state of the beta cell affects expression of both forms of glutamic acid decarboxylase. Pancreas. 1994 Sep;9(5):558-62.
•   Juneja R, Hirsch IB, Naik RG, Brooks-Worrell BM, Greenbaum CJ, Palmer JP
  Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes. Metabolism. 2001 Sep;50(9):1008-13.
•   Keller RJ, Eisenbarth GS, Jackson RA
  Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet. 1993 Apr 10;341(8850):927-8.
•   Kobayashi T, Itoh T, Kosaka K, Sato K, Tsuji K
  Time course of islet cell antibodies and beta-cell function in non-insulin-dependent stage of type I diabetes. Diabetes. 1987 Apr;36(4):510-7.
•   Kobayashi T, Maruyama T, Shimada A, Kasuga A, Kanatsuka A, Takei I, Tanaka S, Yokoyama J
  Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann N Y Acad Sci. 2002 Apr;958:117-30. Review.
•   Kobayashi T, Nakanishi K, Murase T, Kosaka K
  Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes. 1996 May;45(5):622-6.
•   Kobayashi T, Nakanishi K, Sugimoto T, Itoh T, Murase T, Kosaka K, Tsuji K
  Maleness as risk factor for slowly progressive IDDM. Diabetes Care. 1989 Jan;12(1):7-11.
•   Kobayashi T, Tamemoto K, Nakanishi K, Kato N, Okubo M, Kajio H, Sugimoto T, Murase T, Kosaka K
  Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care. 1993 May;16(5):780-8.
•   Kobayashi T
  Subtype of insulin-dependent diabetes mellitus (IDDM) in Japan: slowly progressive IDDM--the clinical characteristics and pathogenesis of the syndrome. Diabetes Res Clin Pract. 1994 Oct;24 Suppl:S95-9. Review.
•   Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P
  Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia. 1996 Jun;39(6):701-9. Erratum in: Diabetologia 1996 Oct;39(10):1245.
•   Lampeter EF, Homberg M, Quabeck K, Schaefer UW, Wernet P, Bertrams J, Grosse-Wilde H, Gries FA, Kolb H
  Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet. 1993 May 15;341(8855):1243-4.
•   Mehta V, Hao W, Brooks-Worrell BM, Palmer JP
  The functional state of the beta cell modulates IL-1 and TNF-induced cytotoxicity. Lymphokine Cytokine Res. 1993 Aug;12(4):255-9.
•   Nakanishi K, Kobayashi T, Inoko H, Tsuji K, Murase T, Kosaka K
  Residual beta-cell function and HLA-A24 in IDDM. Markers of glycemic control and subsequent development of diabetic retinopathy. Diabetes. 1995 Nov;44(11):1334-9.
•   Nakanishi K, Kobayashi T, Miyashita H, Ohkubo M, Sugimoto T, Murase T, Kosaka K, Inouye K, Kono M
  Relationships among islet cell antibodies, residual beta-cell function, and metabolic control in patients with insulin-dependent diabetes mellitus of long duration: use of a sensitive C-peptide radioimmunoassay. Metabolism. 1990 Sep;39(9):925-30.
•   Nakanishi K, Kobayashi T, Sugimoto T, Murase T, Itoh T, Kosaka K
  Predictive value of insulin autoantibodies for further progression of beta cell dysfunction in non-insulin-dependent diabetics. Diabetes Res. 1988 Nov;9(3):105-9.
•   Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J
  Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994 Nov 3;331(18):1188-93.
•   Porte D Jr
  Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes. 1991 Feb;40(2):166-80. Review.
•   Rowley MJ, Mackay IR, Chen QY, Knowles WJ, Zimmet PZ
  Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus. Diabetes. 1992 Apr;41(4):548-51.
•   Sjöberg S, Gunnarsson R, Gjötterberg M, Lefvert AK, Persson A, Ostman J
  Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1987 Apr;30(4):208-13.
•   Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR
  Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes. 1993 Feb;42(2):359-62.
•   Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, Lang DA
  Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med. 1994 Apr;11(3):299-303.
•   Zimmet PZ
  The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity, and demography. Diabetes Care. 1995 Jul;18(7):1050-64. Review.

Rosiglitazone Intervention Study in Patients With Type 1.5 Diabetes

Details for clinical trial NCT00194896